Three Blood Biomarkers Predict Higher Risk of Heart Attack, Stroke in Women

Translate to Spanish or other 102 languages!

Three blood biomarkers could help predict heart attack and stroke risk in women. Image for illustration purposes
Three blood biomarkers could help predict heart attack and stroke risk in women. Image for illustration purposes
- Advertisement -
  • Cardiovascular disease is the leading cause of death in women globally. 
  • There have historically been disparities in diagnosing cardiovascular disease in women as they may have no or different symptoms than men. 
  • Researchers from Brigham and Women’s Hospital found measuring three different biological blood markers can better predict a woman’s risk of having a major cardiovascular event over the next 30 years compared to measuring only one biomarker.

Cardiovascular disease is the leading cause of death in women around the globe, while stroke is the third most commonTrusted Source.

Follow the link to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/3-blood-biomarkers-predict-higher-risk-of-heart-attack-stroke-in-women?slot_pos=article_2&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2024-09-11&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Texas Adds New Condition to Mandatory Newborn Screening Tests

The Texas Department of State Health Services added a new enzyme deficiency test on June 1, 2026, to its newborn screening panel, meaning that all Texas newborns are now tested for 60 rare, genetic conditions. Tests for hearing loss and critical congenital heart disease are additional point-of-service tests typically conducted by the birthing center. 

Pancreatic Cancer Patients Gain Early Access to Experimental Drug Daraxonrasib Following Fast-Track FDA Decision

The U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.

STHS GME Consortium Encourages Community to “Walk with a Doc”, June 6th

Mega Doctor News In an era defined by high-intensity workouts, wearable fitness trackers and advanced training techniques, one of simplest...

Study: Menopause Hormone Therapy Declines Nationwide Despite Proven Benefits

Hormone therapy use among women in the U.S. remains low, even though it's an effective treatment for many menopause symptoms, according to a new Mayo Clinic study published in Mayo Clinic Proceedings.
- Advertisement -